Corrigendum to “Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies” (The Breast (2018) 41(S1) (S11–S12), (S0960977618301760), (10.1016/j.breast.2018.08.033))

Massimo Cristofanilli*, Nadia Harbeck, Hope S. Rugo, Aurelio Castrellon, Anil Abraham Joy, Sunil Verma, Seock Ah Im, Shrividya Iyer, Kathy Puyana Theall, Eric Gauthier, Xin Huang, Cynthia Huang Bartlett, Sibylle Loibl, Richard S. Finn

*Corresponding author for this work

Research output: Contribution to journalComment/debate

Abstract

Two of the authors’ names appeared incorrectly in the byline. The correct names are Anil Abraham Joy and Kathy Puyana Theall.

Original languageEnglish (US)
Number of pages1
JournalBreast
Volume49
DOIs
StatePublished - Feb 2020

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'Corrigendum to “Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies” (The Breast (2018) 41(S1) (S11–S12), (S0960977618301760), (10.1016/j.breast.2018.08.033))'. Together they form a unique fingerprint.

  • Cite this